1
|
Al-Omar HA, Alsowaida N, Aldosari L, Mayet A, Bunyan R, Aljumah M. Exploring physicians' prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods. BMC Neurol 2023; 23:135. [PMID: 37004011 PMCID: PMC10064662 DOI: 10.1186/s12883-023-03184-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 03/26/2023] [Indexed: 04/03/2023] Open
Abstract
BACKGROUND Multiple sclerosis (MS) is the most common disabling neurological disease in young adults worldwide with majority of patients manifest symptoms between 20 and 40 years of age. The aims of this study are to explore physicians' perspectives, views, and behaviors in diagnosing and treating patients with MS in Saudi Arabia and investigate the prescribing pattern of disease-modifying therapies (DMTs). METHODS A sequential explanatory mixed-method approach was used to achieve the study objectives. The quantitative arm of the study consisted of patient data extracted from the Saudi MS registry from 2015 to 2018. The qualitative study consisted of in-depth semi-structured interviews with physicians using a validated interview topic guide comprising 28 open-ended questions. RESULTS We extracted data of 2,507 patients from 20 different hospitals across Saudi Arabia. Patients' mean age was 34 ± 10 years; two-thirds (n = 1,668) were female. 92% (n = 2,292) had relapsing-remitting multiple sclerosis, and 5% (n = 126) had secondary-progressive multiple sclerosis. In general, patients with MS received at least one drug as the DMT or DMTs and corticosteroids for those with relapse. Qualitatively, nine physicians agreed to participate in the interviews. Of them, five (55%) were male and four were female from different regions. Thematic analysis yielded three main themes: practice, views, and challenges. CONCLUSIONS The prevalence of MS in Saudi Arabia is raising but is still much lower than that reported in the Gulf region. A national MS guideline is needed to streamline diagnosis and treatment criteria, avoid any delay in treatment, and guide physicians who provide care for patients with MS.
Collapse
Affiliation(s)
- Hussain Abdulrahman Al-Omar
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box: 2457, Riyadh, 11451, Saudi Arabia.
- Health Technology Assessment Unit (HTAU), College of Pharmacy, King Saud University, P.O. Box: 2457, Riyadh, 11451, Saudi Arabia.
| | - Nada Alsowaida
- Department of Pharmacy Services, King Saud University Medical City, P.O. Box: 2457, Riyadh, 11472, Saudi Arabia.
| | - Lama Aldosari
- Department of Pharmacy, Maternity and Children Hospital, Ministry of Health, Al Kharj, 16278, Saudi Arabia
| | - Ahmed Mayet
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box: 2457, Riyadh, 11451, Saudi Arabia
| | - Reem Bunyan
- Department of Neurology, Neurosciences Center, King Fahd Specialist Hospital, Dammam, 32253, Saudi Arabia
| | - Mohammed Aljumah
- Department of Neurology, King Fahad Medical City, Ministry of Health, Riyadh, 11525, Saudi Arabia.
| |
Collapse
|
2
|
A Systematic Review and Meta-Analysis of the Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) International Validations. J Clin Med 2023; 12:jcm12020703. [PMID: 36675637 PMCID: PMC9863826 DOI: 10.3390/jcm12020703] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 01/03/2023] [Accepted: 01/09/2023] [Indexed: 01/17/2023] Open
Abstract
Cognitive impairment is a prevalent and debilitating symptom of multiple sclerosis (MS) but is not routinely addressed in clinical care. The Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) was developed in 2012 to screen and monitor MS patients’ cognition. This systematic review and meta-analysis aimed to identify, synthesise, and critically appraise current BICAMS’ international validations. The literature search was conducted using PubMed, PsycINFO and Web of Science electronic databases in August 2022. Quantitative, peer-reviewed adult studies, which followed the BICAMS international validation protocol and were published in English, were included. The search identified a total of 203 studies, of which 26 were eligible for inclusion. These reported a total of 2833 adults with MS and 2382 healthy controls (HC). The meta-analysis showed that BICAMS identified impaired cognitive functioning in adults with MS compared to HC for all three subtests: information processing speed (g = 0.854, 95% CI = 0.765, 0.944, p < 0.001), immediate verbal recall (g = 0.566, 95% CI = 0.459, 0.673, p < 0.001) and immediate visual recall (g = 0.566, 95% CI = 0.487, 0.645, p < 0.001). Recruitment sites and strategies limit the generalisability of results. BICAMS is a valid and feasible international MS cognitive assessment.
Collapse
|
3
|
Sarsak HI. The Modified Interest Checklist: Translation and Cultural Adaptation Among an Arabic-Speaking Inpatient Psychiatric Sample. Am J Occup Ther 2022; 76:23873. [PMID: 35900365 DOI: 10.5014/ajot.2022.049262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
IMPORTANCE People with mental disorders usually have emotional, behavioral, and physical health problems, such as decreased enjoyment of life and lack of interest. It is important to have an assessment to measure these problems because interest is a powerful psychological state that makes people fully engaged and focused. Measuring people's level of interest provides an understanding of their needs, behaviors, thoughts, and personalities. OBJECTIVE To develop and culturally adapt the Arabic translation of the Modified Interest Checklist for Arabic-speaking clients with psychiatric disorders. DESIGN A multistage process involving cognitive debriefing and back translation. SETTING Two inpatient mental health hospitals in Saudi Arabia. PARTICIPANTS Eighty-eight English- and Arabic-speaking adult clients with psychiatric disorders. RESULTS Significant moderate agreement was found between the scores obtained from the two versions (p < .000). The κ measurement of agreement was 0.59 (95% confidence interval [0.42, 0.76]). CONCLUSIONS AND RELEVANCE The Arabic translation of the Modified Interest Checklist was generated for potential use in research and clinical practice with Arabic-speaking clients with psychiatric disorders and mental health conditions. Further validation of the developed Arabic version is imperative. What This Article Adds: This brief report provides a culturally adapted Arabic translation of the Modified Interest Checklist that could be useful to rehabilitation professionals who would like to use this checklist for Arabic-speaking clients with psychiatric disorders and mental health conditions.
Collapse
Affiliation(s)
- Hassan Izzeddin Sarsak
- Hassan Izzeddin Sarsak, PhD, OT, is Assistant Professor, Occupational Therapy Program, Batterjee Medical College, Jeddah, Saudi Arabia;
| |
Collapse
|
4
|
The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): Validation in Arabic and Lebanese Normative Values. J Int Neuropsychol Soc 2022; 28:94-103. [PMID: 33563350 DOI: 10.1017/s1355617721000102] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE Multiple sclerosis (MS) is often associated with cognitive deficits. Accurate evaluation of the MS patients' cognitive performance is essential for diagnosis and treatment recommendation. The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS), widely used cognitive testing battery, examines processing speed, verbal and visuospatial learning, and memory. Our study aims to examine the psychometric properties of an Arabic version of the BICAMS and to provide normative values in a Lebanese sample. METHOD The BICAMS, comprised of the Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT-R), and a newly developed verbal learning/memory test, the Verbal Memory Arabic Test (VMAT), were administered on healthy subjects and MS patients. The sample consisted of 180 healthy individuals, of whom 63 were retested after 2-3 weeks. Forty-three MS patients matched with 43 healthy subjects based on age, sex, and years of education were assessed. A sample of 10 MS patients was also examined on two occasions. Test-retest reliability and criterion-related validity were examined, and regression-based norms were derived. RESULTS The test-retest correlations showed good evidence of reliability with coefficients ranging between 0.64 and 0.73 in the healthy sample, and between 0.43 and 0.92 in the MS sample. The BICAMS was able to discriminate between MS patients and matched healthy participants on the SDMT and BVMT-R. Normative data were comparable to other studies. CONCLUSIONS This new Arabic version of the BICAMS shows initial good psychometric properties. While good evidence of VMAT's reliability was shown in the healthy participants, less test-retest reliability in this tool was seen in the MS group, and partial criterion-related validity was evident. This renders further examination of the VMAT. We provide regression-based norms for a Lebanese sample and encourage the use of this battery in both research and clinical settings.
Collapse
|
5
|
Tunisian version of the brief international cognitive assessment for multiple sclerosis: Validation and normative values. Mult Scler Relat Disord 2021; 58:103444. [PMID: 34929452 DOI: 10.1016/j.msard.2021.103444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Revised: 11/30/2021] [Accepted: 12/01/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND The Brief International cognitive assessment for Multiple sclerosis (BICAMS) is a specific batterie used to identify cognitive impairment in Multiple Sclerosis (MS) in a reliable and easy way. To date, for the Arabic-speaking Tunisian MS patients, there is no consensus for the use of specific cognitive batteries in MS. OBJECTIVE The aim of our work was to develop and validate the Tunisian version of the BICAMS (T-BICAMS) and to determine our own normative values. MATERIAL AND METHODS Patients diagnosed with MS and followed up in the department of Neurology of Razi Hospital were recruited and matched to healthy controls according to age, sex and educational level. T-BICAMS validity was established by comparing MS and healthy controls for symbol digit modalities test (SDMT), brief visual memory test (BVMT-R) and Tunisian verbal learning tests (TVLT) which was used instead of the California verbal learning test (CVLT-II). RESULTS The 104 MS patients and 104 healthy controls were comparable for age, sex and educational level. The MS group exhibited lower performances in all T-BICAMS domains compared to healthy controls: SDMT (x003Dp<10-3), BVMT-R (p = 0.002) and TVLT (p x003D<10-3). T-BICAMS Cronbach alpha value was 0.741. Normative values were identified for patients with MS: SDMT [39-40], BVMT-R [26-27] and TVLT [43-44]. Cognitive impairment was identified among 76 patients (73.1%). Males, lower educational levels and progressive MS were associated with a more severe cognitive impairment. CONCLUSIONS The current study has established the BICAMS as a valid and reliable tool for the identification of cognitive impairment in the Tunisian MS population.
Collapse
|
6
|
Rosca EC, Simu M. Montreal cognitive assessment for evaluating cognitive impairment in multiple sclerosis: a systematic review. Acta Neurol Belg 2020; 120:1307-1321. [PMID: 32996098 DOI: 10.1007/s13760-020-01509-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 09/19/2020] [Indexed: 12/13/2022]
Abstract
This study aims to systematically review the evidence on the accuracy of the Montreal Cognitive Assessment (MoCA) test for evaluating the presence of cognitive impairment in patients with multiple sclerosis (MS) and to outline the quality and quantity of research evidence available about the use of MoCA in this population. We conducted a systematic literature review, searching five databases from inception until May 2020. We identified fourteen studies that met the inclusion criteria: three cross-sectional studies and two case - control studies comparing MoCA to a battery of tests, one study comparing MoCA to Mini-Mental State Examination (MMSE), and eight studies estimating the prevalence of cognitive impairment in individuals with MS. Publication period ranged from 2012 to 2020. Although the MoCA test demonstrated good sensitivity and specificity when used at the recommended threshold of 26, a lower threshold than the original cut-off was also reported to be useful for optimal screening, as it lowers false positive rates and improves diagnostic accuracy. Furthermore, in MS patients without subjective cognitive complaints, a cutoff of 27 could provide a better balance between the sensitivity and the specificity of the test. In patients with MS, the MoCA provides information on general cognitive functions disturbances. Nonetheless, more studies are required to examine the optimum cut-off score for detecting cognitive impairments in MS patients.
Collapse
Affiliation(s)
- Elena Cecilia Rosca
- Department of Neurology, University of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.
- Department of Neurology, Clinical Emergency County Hospital, Bd. Iosif Bulbuca nr. 10, 300736, Timisoara, Romania.
| | - Mihaela Simu
- Department of Neurology, University of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania
- Department of Neurology, Clinical Emergency County Hospital, Bd. Iosif Bulbuca nr. 10, 300736, Timisoara, Romania
| |
Collapse
|
7
|
Alboudi A, Hadid A, Ali AR, Alshaikh F, Aqleh H. Normative values of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in an Arab population: Corrected for age, sex and education. Mult Scler Relat Disord 2020; 44:102305. [PMID: 32570183 DOI: 10.1016/j.msard.2020.102305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Revised: 06/01/2020] [Accepted: 06/12/2020] [Indexed: 11/30/2022]
Abstract
Background Cognitive impairment is common in multiple sclerosis (MS) patients with 43-70% of patients being affected. The international cognitive assessment for MS BICAMS is a new battery for cognitive assessment in MS patients. It was suggested in 2012 that international validation efforts be undertaken. Objective To utilize regression to provide normative values for the BICAMS while correcting for age, gender and education, as well as assess test-retest reliability, in an Arab population. Methods Healthy subjects were recruited from different areas in Dubai. Corrections for demographics were calculated using multiple linear regression. Test-retest reliability was assessed using the Pearson correlation coefficient. Results Two hundred eighty-one healthy subjects were enrolled (174 women, mean age 30±10.3 years, mean education 17.8±3.7 years). Test re-test results showed significant correlation between baseline and retest scores. Regression-based equations were derived for the BICAMS. Conclusion This large-scale validation study provides evidence to support the facilitation of international implementation of the BICAMS assessment by focusing on the Arab population. Next steps include validation efforts in an Arab MS patient population to further support the use of the BICAMS in day to day practice and for longitudinal patient assessment.
Collapse
Affiliation(s)
- Ayman Alboudi
- Mercy Health Saint Mary, Grand Rapids, Michgan, US; Rashid hospital, Dubai, UAE.
| | | | | | | | | |
Collapse
|
8
|
AlJumah M, Bunyan R, Al Otaibi H, Al Towaijri G, Karim A, Al Malik Y, Kalakatawi M, Alrajeh S, Al Mejally M, Algahtani H, Almubarak A, Cupler E, Alawi S, Qureshi S, Nahrir S, Almalki A, Alhazzani A, Althubaiti I, Alzahrani N, Mohamednour E, Saeedi J, Ishak S, Almudaiheem H, El-Metwally A, Al-Jedai A. Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. BMC Neurol 2020; 20:49. [PMID: 32035478 PMCID: PMC7007659 DOI: 10.1186/s12883-020-1629-3] [Citation(s) in RCA: 57] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2019] [Accepted: 01/24/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. METHOD In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. RESULTS As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia. CONCLUSION The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia.
Collapse
Affiliation(s)
| | - R Bunyan
- King Fahd Specialist Hospital (KFSH)-Dammam, Dammam, Saudi Arabia
| | - H Al Otaibi
- King Fahd General Hospital-Jeddah, Jeddah, Saudi Arabia
| | - G Al Towaijri
- King Fahd Medical City (KFMC), MOH, Riyadh, Saudi Arabia
| | - A Karim
- King Fahd General Hospital-Al-Madinah, Riyadh, Saudi Arabia
| | - Y Al Malik
- King Abdulaziz Medical City (National Guard Health Affairs)-Riyadh, Riyadh, Saudi Arabia.,King Saud bin Abdulaziz University For Health Sciences, Riyadh, Saudi Arabia
| | | | - S Alrajeh
- Dr. Sulaiman Al Habib Hospital-Olaya Branch, Riyadh, Saudi Arabia
| | | | - H Algahtani
- King Abdul-Aziz Medical City (National Guard Health Affairs), Jeddah, Saudi Arabia
| | | | - E Cupler
- King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia
| | - S Alawi
- Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - S Qureshi
- Johns Hopkins Aramco Healthcare Company (JHAH), Dhahran, Saudi Arabia
| | - S Nahrir
- King Saud Medical City, Riyadh, Saudi Arabia
| | - A Almalki
- King Abdul-Aziz Hospital and Oncology Center, Jeddah, Saudi Arabia
| | | | - I Althubaiti
- King Fahad Military Medical Complex, Dhahran, Saudi Arabia
| | - N Alzahrani
- King Fahd General Hospital, Baha, Saudi Arabia
| | - E Mohamednour
- King Fahad Specialist Hospital, Dammam, Qassim, Saudi Arabia
| | - J Saeedi
- King Abdullah Bin Abdulaziz University Hospital, Riyadh, Saudi Arabia
| | - S Ishak
- Itkan Health Consulting, Riyadh, Saudi Arabia
| | - H Almudaiheem
- Ministry of Health, Deputyship of Therapeutic Affairs, Riyadh, Saudi Arabia
| | - A El-Metwally
- King Saud bin Abdulaziz University For Health Sciences, Riyadh, Saudi Arabia
| | - A Al-Jedai
- Ministry of Health, Deputyship of Therapeutic Affairs, Riyadh, Saudi Arabia
| |
Collapse
|